Efficacy of nucleos(t)ide analogues(NAs) in preventing virus reactivation in oncology patients with HBV infection after chemotherapy or surgery: A network meta-analysis

被引:1
作者
Zhao, Yuqing [1 ,2 ]
Song, Yingying [2 ]
Zhang, Huan [1 ,2 ]
Qu, Tongshuo [1 ,2 ]
Axinbai, Malina [1 ,2 ]
Yang, Yidian [1 ,2 ]
Zhang, Liping [1 ,2 ]
机构
[1] Beijing Univ Chinese Med, Grad Sch, Beijing, Peoples R China
[2] Beijing Univ Chinese Med, Dongfang Hosp, Dept Gastroenterol, Beijing, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2023年 / 12卷
关键词
HBV reactivation; cancer patients; antiviral therapy; survival rate; chemotherapy disruption; network meta-analysis; HEPATITIS-B-VIRUS; ANTIVIRAL THERAPY; TRANSARTERIAL CHEMOEMBOLIZATION; HEPATOCELLULAR-CARCINOMA; LAMIVUDINE; MANAGEMENT; ENTECAVIR; SURVIVAL; CANCER; PROPHYLAXIS;
D O I
10.3389/fonc.2022.1050714
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: In this study, we aimed to perform a network meta-analysis to compare the effectiveness of NAs in decreasing the reactivation of HBV, reducing chemotherapy disruption, and improving survival in oncology patients. Methods: Relevant randomized controlled trials (RCT) evaluating the impact of NAs in HBV infected-related oncology patients were retrieved from electronic databases. The outcome indicators included reactivation rate, survival rate of 1 to 3 years after treatment, and chemotherapy disruption rate. The studies were evaluated for bias using the RCT risk of bias assessment tool recommended in the Cochrane Handbook. The risk ratio (RR) was used to compare the outcome indicators for the anti-viral treatment, and the surface under the cumulative ranking curves (SUCRA) was used to identify the optimal therapeutic regime. Results: A total of 67 trials containing 5722 patients were included in this study. Regarding the reduction of reactivation rate, entecavir, lamivudine, adefovir alone were less effective than the combination of lamivudine and entecavir (94.9%), with RR values ranging from 3.16 to 3.73. However, based on SUCRA, the efficacy of telbivudine (80.3%) and the combination of lamivudine and adefovir dipivoxil (58.8%) were also acceptable. Entecavir (RR values ranging from 1.25 to 1.50) and lamivudine (RR values ranging from 1.27 to 1.35) can prolong the survival rate of patients at 1-3 years, and were better than adefovir dipivoxil in the comparison of 1-year survival rate. The RR values were 1.18 and 1.19, respectively. And entecavir 's ranking in SUCRA was more stable. Entecavir, lamivudine, and tenofovir all reduced chemotherapy interruption rates compared with no antiviral therapy, especially for tenofovir. Conclusions: Current evidence shows that lamivudine combined with entecavir, telbivudine, and lamivudine combined with adefovir dipivoxil were the most effective in preventing virus reactivation in HBV infected-related cancer patients treated with chemotherapy. Entecavir had the most stable effect on survival, while tenofovir had the best impact on reducing the chemotherapy disruption rate. Due to limited quality and quantity of the included studies, more high-quality studies are required to verify the above conclusions.
引用
收藏
页数:11
相关论文
共 93 条
[21]   A Long-Term Follow-Up and Comprehensive Observation of Risk and Prognosis Factors of Recurrence and Survival After Resection of Hepatocellular Carcinoma [J].
Hu, Lei ;
Xue, Feng ;
Li, Yunyun ;
Shao, Minhua ;
Sun, Yanfu ;
Wei, Gongtian .
CELL BIOCHEMISTRY AND BIOPHYSICS, 2014, 69 (03) :421-431
[22]  
Hu RH, 2017, MODERN DIAGNOSIS TRE, V28, P4268
[23]   Antiviral Therapy Reduces Hepatocellular Carcinoma Recurrence in Patients With Low HBV-DNA Levels A Randomized Controlled Trial [J].
Huang, Gang ;
Li, Peng-peng ;
Lau, Wan Yee ;
Pan, Ze-ya ;
Zhao, Ling-hao ;
Wang, Zhen-guang ;
Wang, Meng-chao ;
Zhou, Wei-ping .
ANNALS OF SURGERY, 2018, 268 (06) :943-954
[24]   Antiviral Therapy Improves Postoperative Survival in Patients With Hepatocellular Carcinoma A Randomized Controlled Trial [J].
Huang, Gang ;
Lau, Wan Yee ;
Wang, Zhen-Guang ;
Pan, Ze-Ya ;
Yuan, Sheng-Xian ;
Shen, Feng ;
Zhou, Wei-Ping ;
Wu, Meng-Chao .
ANNALS OF SURGERY, 2015, 261 (01) :56-66
[25]  
Huang H, 2014, JAMA-J AM MED ASSOC, V312, P2521, DOI 10.1001/jama.2014.15704
[26]   Antiviral therapy decreases viral reactivation in patients with hepatitis B virusrelated hepatocellular carcinoma undergoing hepatectomy: a randomized controlled trial [J].
Huang, L. ;
Li, J. ;
Yan, J. ;
Sun, J. ;
Zhang, X. ;
Wu, M. ;
Yan, Y. .
JOURNAL OF VIRAL HEPATITIS, 2013, 20 (05) :336-342
[27]   Management of hepatitis B reactivation in patients receiving cancer chemotherapy [J].
Huang, Yi-Wen ;
Chung, Raymond T. .
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2012, 5 (05) :359-370
[28]   Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy [J].
Ijaz, Samreen ;
Arnold, Catherine ;
Dervisevie, Samir ;
Mechurova, Jana ;
Tatman, Nick ;
Tedder, Richard S. ;
Naouirnov, Nikolai V. .
JOURNAL OF MEDICAL VIROLOGY, 2008, 80 (07) :1160-1170
[29]   A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization [J].
Jang, JW ;
Choi, JY ;
Bae, SH ;
Yoon, SK ;
Chang, UI ;
Kim, CW ;
Cho, SH ;
Han, JY ;
Lee, YS .
HEPATOLOGY, 2006, 43 (02) :233-240
[30]  
Jiang SH, 2017, J N SICHUAN MED COLL, V32, P701